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Abstract 
Multi-Drug Resistant (MDR) Pseudomonas aeruginosa is one of the most important bacterial pathogens that causes 
infection with a high mortality rate due to resistance to different antibiotics. This bacterium prompts extensive tissue 
damage with varying factors of virulence, and its biofilm production causes chronic and antibiotic-resistant infec-
tions. Therefore, due to the non-applicability of antibiotics for the destruction of P. aeruginosa biofilm, alternative 
approaches have been considered by researchers, and phage therapy is one of these new therapeutic solutions. 
Bacteriophages can be used to eradicate P. aeruginosa biofilm by destroying the extracellular matrix, increasing the 
permeability of antibiotics into the inner layer of biofilm, and inhibiting its formation by stopping the quorum-sensing 
activity. Furthermore, the combined use of bacteriophages and other compounds with anti-biofilm properties such 
as nanoparticles, enzymes, and natural products can be of more interest because they invade the biofilm by various 
mechanisms and can be more effective than the one used alone. On the other hand, the use of bacteriophages for 
biofilm destruction has some limitations such as limited host range, high-density biofilm, sub-populate phage resist-
ance in biofilm, and inhibition of phage infection via quorum sensing in biofilm. Therefore, in this review, we specifi-
cally discuss the use of phage therapy for inhibition of P. aeruginosa biofilm in clinical and in vitro studies to identify 
different aspects of this treatment for broader use.
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Introduction
Pseudomonas aeruginosa is a Gram-negative bacillus and 
one of the main opportunistic pathogens that have a lead-
ing role in nosocomial, acute, and chronic infections [1]. 
Infection with this pathogen leads to diseases with a high 
mortality rate in patients diagnosed with cystic fibrosis, 
cancer, severe burns, and immunocompromised patients 
[2, 3]. This bacterium can survive on water, different sur-
faces, and medical devices by using its influential bind-
ing factors such as flagella, pili, and biofilms. Thus, P. 
aeruginosa is abundant in natural and artificial environ-
ments, lakes, hospitals, and household sink drains [4].
Due to the widespread role of this bacterium in caus-
ing various infections and increasing antibiotic resist-
ance, recently, the treatment failure has become a major 
global problem. P. aeruginosa has shown high intrinsic 
resistance to a range of antibiotics, including beta-lac-
tams, fluoroquinolones, and aminoglycosides, which 
results in significant morbidity and mortality rates [5, 
6]. According to U.S. Centers for Disease Control and 
Prevention report, it is estimated that approximately 
51,000 healthcare-associated infections caused by P. aer-
uginosa occur in the United States each year, and 13% 
of these infections are multidrug-resistant (MDR), with 
roughly 400 deaths per year attributed to such infec-
tions [7, 8]. The main mechanisms of these resistances 
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are low antibiotic permeability of the outer membrane, 
chromosomally encoded AmpC, and drug efflux via 
multi-drug efflux (Mex) systems [9]. In addition to intrin-
sic resistance, P. aeruginosa has different mechanisms 
for resistance to various antibiotics, such as horizontal 
gene transfer and mutation-driven resistance [6, 10, 11]. 
Mobile genetic elements such as transposons, resistance 
islands, prophages, integrons, and plasmids can accom-
modate antibiotic resistance genes and transmit them 
to P. aeruginosa, causing MDR bacteria. For example, 
aminoglycoside-modifying enzymes are transported to 
P. aeruginosa via mobile genetic elements and reduce the 
binding affinity of the antibiotic to its target site, which is 
the  30S ribosomal subunit. Therefore, it causes resistance 
to aminoglycosides [12]. Furthermore, the random muta-
tion frequency differs between antibiotics with resistance 
frequencies ranging from  106 to  109 for individual anti-
biotics. The rate of mutation can increase in some situa-
tions, such as the presence of DNA-damaging agents or 
within growth in a biofilm [6].
Pseudomonas aeruginosa can bind to various sur-
faces and form biofilms leading to chronic infections by 
increasing resistance to antibiotics, disinfectants, vari-
ous irradiation treatments, environmental conditions, 
and the immune system [3, 13, 14]. Bacterial biofilm was 
introduced, for the first time, in 1987 as a community of 
microorganisms capable of binding to surfaces and form-
ing an exopolysaccharide and extracellular matrix [15]. 
Biofilms are approximately 10 to 1000 times more resist-
ant to antibiotics than planktonic cells due to the lack 
of antibiotic penetration into the complex polysaccha-
ride matrix (glycocalyx) of biofilms [16, 17]. Thus, bio-
films and the inherent and acquired antibiotic resistance 
mechanism of P. aeruginosa have increased the preva-
lence of MDR strains in recent years with virtually no 
fully effective antibiotics available to stop this bacterium.
So, researchers are looking for new ways to inhibit P. 
aeruginosa biofilms. Phage  therapy is one of the impor-
tant methods to inhibit P. aeruginosa biofilm [18]. Bac-
teriophages are viruses that invade bacteria; they were 
discovered almost a century ago and are divided into two 
lytic (virulent phages) and temperate categories depend-
ing on their life cycle [19, 20]. After attaching to their 
host, the lytic phages inject their genetic materials into 
the host chromosome and replicate along with the host 
cell DNA, then disperse via the host lysis to repeat the 
infection cycle for other hosts. Of note, obligately lytic 
bacteriophages are often a matter of interest for thera-
peutic purposes because they lead to the killing of their 
bacterial host cell rapidly [21]. On the other hand, tem-
perate phages generally integrate their genome into the 
host chromosome or sometimes keep it as a plasmid, 
which is transmitted to the daughter cells by cell division 
[21, 22]. Using antibiotics has always been a good solu-
tion for the treatment of bacterial infections due to their 
inexpensive cost and extreme effectiveness on various 
bacterial agents. After World War II, the widespread 
effective use of antibiotics diminished the interest of dif-
ferent societies in using bacteriophages [23, 24]. Nev-
ertheless, over the years, for various reasons such as 
overuse and misuse of broad-spectrum antibiotics, bac-
terial resistance to the existing antibiotics increased, and 
MDR strains dramatically expanded worldwide. This sit-
uation forced scientists to think about reusing bacterio-
phages instead of antibiotics to treat bacterial infections 
[25, 26].
Bacteriophages that specifically target Pseudomonas 
genus were first discovered in the middle of the twentieth 
century, and due to the great role of this microorganism 
in nosocomial infections and high antibiotic resistance, 
using bacteriophages to inhibit P. aeruginosa has been 
highly regarded [27, 28]. The use of two or more bacte-
riophage mixtures with different host ranges in a single 
suspension as a bacteriophage cocktail is usually more 
effective for inhibiting bacterial infections [29, 30]. Bac-
teriophage cocktail causes better reduction of bacterial 
density and improve bacteriophages’ efficiency, and also 
in  vitro studies have shown that bacteriophage cock-
tail result in a higher reduction in P. aeruginosa infec-
tions [31]. Bacteriophage cocktails can easily penetrate 
the P. aeruginosa biofilm and destroy its structure by 
inducing the synthesis of enzymes such as polysaccha-
ride depolymerase [32]. Polysaccharide depolymerase, 
a polysaccharide hydrolase encoded by bacteriophages, 
can specifically degrade the macromolecule carbohy-
drates of the host bacterial envelope. This enzyme helps 
the bacteriophage to adsorb, invade, and disintegrate the 
host bacteria [33]. Furthermore, bacteriophages generate 
peptidoglycan hydrolases enzymes, called Endolysins, at 
the end of the lytic cycle. They decompose peptidogly-
can from the inside and assist in forming new progeny 
phages to release from the cell [34]. Endolysins are always 
proposed as antibacterial agents because of their high 
specific activity and unique mode of action against bac-
teria. The activity of Endolysins is independent of anti-
biotic susceptibility patterns [35, 36]. It should be noted 
that bacteriophages have advantages over antibiotics to 
inhibit infections caused by bacterial biofilms. For exam-
ple, bacteriophages penetrate the inner layer of the bio-
film, unlike antibiotics that affect bacteria at the surface. 
Furthermore, bacteriophages are capable of infecting 
persister cells and destroying them if they are reactivated. 
They can also dissolve the biofilm matrix by producing 
an enzyme or induce enzyme production by the bacte-
rial host [37–39]. Another mechanism of biofilm inhibi-
tion by bacteriophages is the production of enzymes that 
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inhibit biofilm production. One study reported that bac-
teriophages can inducing synthesis of quorum quenching 
(QQ) lactonase by genetic modification, which inhibits 
biofilm formation in P. aeruginosa by hydrolysis of Acyl 
homoserine lactones (AHL) and inhibition of quorum-
sensing (QS) activity [40].
Therefore, regarding the determinant role of P. aerugi-
nosa biofilm in the development of antibiotic resistance 
and chronic infections, finding new strategies as a treat-
ment for its inhibition is essential. In this review, we will 
specifically discuss the role of bacteriophages in the inhi-
bition and destruction of P. aeruginosa biofilm to identify 
various aspects of phage therapy in this field and facili-
tate its possible widespread use in clinical practice.
Phage therapy for inhibition of MDR P. aeruginosa 
biofilm: in vitro studies
Many studies have indicated that bacteriophages are one 
of the most promising weapons for the elimination of 
in vitro P. aeruginosa biofilms; for example, Adnan et al. 
used bacteriophage M-1 that was isolated from waste-
water to remove biofilms caused by MDR isolates of P. 
aeruginosa. The results showed that the bacteriophage 
MA-1 reduced the growth rate of P. aeruginosa and 
decreased biofilms after 6 h of treatment. An important 
point discussed in this study was that bacteriophage can 
degrade alginate polymers through enzymatic activities, 
and even it can destroy the 20-day biofilm formed by P. 
aeruginosa. Phage can also destroy biofilms indirectly by 
killing bacteria before attaching, or after colonizing the 
surface [41]. Another study examined the effect of PB1-
like, phiKZ-like, and LUZ24-like phages against MDR P. 
aeruginosa under variable growth conditions; the results 
indicated that each phage alone was able to suppress 
planktonic and biofilm form of MDR isolates. The phiKZ-
like viruses were the most potent phages in the suppres-
sion of planktonic form. Besides, LUZ24-like phage was 
the most effective phage to destroy the biofilm of antibi-
otic-resistant isolates. Also, the effect of the cocktail con-
sisting of all three phages was more potent than that of 
each phage alone. Researchers attributed the small size 
of the LUZ24-like phage to its significant effect on bio-
film degradation, while a high volume phiKZ-like phage 
had the least destructive effect on the biofilm. Also, it 
has been suggested that phages may not have an excel-
lent effect on high-density biofilms. However, they can 
prevent further accumulation and diffusion of biofilms by 
reducing migratory bacteria [42].
Fong et  al. used bacteriophages Pa193, Pa204, Pa222, 
and Pa223 to eliminate the biofilm of P. aeruginosa iso-
lated from patients with chronic rhinosinusitis and found 
that a single dose of these phages alone and in cocktail 
significantly decreased the rate of biofilm production 
after 24 and 48  h of treatment. Although single phages 
reduced 53–73% of the biofilms of the isolates, the effi-
cacy of the phage cocktail on the biofilms increased by 
89%. Also, they suggested that using cocktail phages 
increased activity by expanding the host range and pre-
venting the formation of bacteriophage-resistant mutant 
bacteria. Notably, the anti-biofilm activity of a cocktail 
of four phages was not affected by multidrug resistance 
[43]. In 2017, in a study, researchers isolated bacterio-
phage AZ1 and tested its anti-biofilm activity against 
MDR P. aeruginosa. The results confirmed the inhibi-
tory and destructive activity of phage AZ1 against P. 
aeruginosa in planktonic and biofilm cells. Researchers 
suggested that the mechanism of natural phages was to 
penetrate the biofilm; however, complete eradication 
may require a combination of phages.[44]. The results of 
another study on a new phage endolysin, LysPA26, which 
was tested against planktonic form and P. aeruginosa bio-
film, showed that the phages had a significant effect on a 
wide range of MDR Gram-negative bacteria (Acinetobac-
ter baumannii, Klebsiella pneumoniae, P. aeruginosa, and 
Escherichia coli) on planktonic form and also eliminated 
P. aeruginosa biofilm. Interestingly, the result showed 
that LysPA26 had high antibacterial activity against P. 
aeruginosa isolates by influencing the outer membrane 
under 100 °C heat treatment. The mechanism of biofilm 
degradation in a concentration-dependent manner by 
LysPA26 is still unclear and needs further studies [45].
Kwiatek et  al. investigated the effects of two bacterio-
phages MAG1 and MAG4, and their capability to con-
trol carbapenem-resistant P. aeruginosa in planktonic and 
biofilm models. It was found that each phage individu-
ally affected approximately 50% of P. aeruginosa isolates, 
but when they were used as a cocktail, the anti-biofilm 
property was increased to 72.9%. Although MAG4 effec-
tively reduced biofilm shortly after the treatment, MAG1 
affected biofilm after a more extended period. This study 
also reported that bacteriophages can utilize three differ-
ent mechanisms for the eradication of biofilms, including 
lysis biofilm-forming bacteria by typical phage infection 
(lysis from within), production of extracellular polymeric 
substance (EPS) depolymerase, and "lysis from without" 
that does not need for phage gene expression after absorp-
tion. It was also suggested that YefM antitoxin of the bacte-
rial toxin-antitoxin system as a MAG1-encoded homolog 
might increase the effectiveness of MAG1 over MAG4 
[46]. In another experimental study, it was reported that 
ФKMV, ФPA2, ФPaer4, and ФE2005 phages, either indi-
vidually or as a cocktail, were capable of destroying biofilm 
of MDR P. aeruginosa isolates in a dose-dependent man-
ner in 24-h assays. In this study, the phage cocktail was not 
active against two isolates after biofilm formation because 
of the high production of alginate that its accumulation 
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inhibits phage anti-biofilm activity during 24 h. However, 
in the conditions with pre-existing biofilm formation, the 
phages affected these two resistant isolates and eliminated 
the alginate, which was produced immediately after infec-
tion [47]. In another study, the effects of bacteriophages 
vB-Pa4 and vB-Pa5 on the formation and development 
of MDR P. aeruginosa biofilms were investigated, and the 
results suggested that bacteriophages almost prevented 
biofilm formation and also pre-formed biofilms were par-
tially destroyed by phage. Ahiwale et al., in an in vitro study, 
investigated the management of biofilm produced by anti-
biotics resistant P. aeruginosa using native BVPaP-3 phage. 
It was found that T7-like lytic phage (BVPaP-3) could 
inhibit the biofilm formation (three logs) of hospital iso-
lates of P. aeruginosa. Also, it was able to disperse pre-made 
biofilms of all isolates after 24 h [48]. Furthermore, bacteri-
ophage PA1Ø was tested against P. aeruginosa biofilm, and 
it was found that the bacteriophage had lytic properties and 
required bacterial type IV pili to infect P. aeruginosa iso-
lates. Phage PA1Ø had bactericidal activity against a wide 
range of bacteria (both Gram-positive and Gram-negative), 
and it was able to eradicate biofilm. This phage can also 
be introduced as an antimicrobial agent for the treatment 
of biofilm-associated mixed infections of Staphylococcus 
aureus and P. aeruginosa. Due to the probable production 
of lytic phage enzymes, the mechanism of phage antibac-
terial action against Gram-positive bacteria may be differ-
ent from that of P. aeruginosa. For example, endolysin can 
degrade the cell wall of Gram-positive bacteria by destroy-
ing peptidoglycan [49].
Based on the above studies, it can be concluded that the 
identification of new phages can be an excellent alternative 
to antimicrobial agents for the treatment of MDR P. aerugi-
nosa biofilm and may even eradicate the infections caused by 
MDR P. aeruginosa mixed with bacteria in vitro. The results 
of in vitro investigations can help to increase the application 
of phages against MDR P. aeruginosa nosocomial infections. 
The use of bacteriophage cocktails can increase anti-biofilm 
performance and also prevent resistance to bacteriophages. 
Besides, the production of large amounts of alginate or 
mature biofilms can inhibit the function of phages, so they 
should be investigated further in future studies. It should be 
noted that, due to the very high importance of MDR strains, 
in this section, we have discussed bacteria with high antibi-
otic resistance; also, in Table 1, a complete list of studies that 
have applied bacteriophages to inhibit other P. aeruginosa 
species biofilm is presented.
Phage therapy for inhibition of MDR P. aeruginosa 
biofilm: in vivo studies
Various studies have shown advances in using phages 
against MDR P. aeruginosa, which cause chronic otitis 
media, cystic fibrosis, and burn wounds; however, these 
studies are limited to pre-clinical evaluations [62–64]. It 
should be noted that applying phages as antimicrobial 
agents for the control of pathogens is not a new approach, 
and it has been used since the phage was discovered. For 
example, it was used in Eastern Europe and the former 
Soviet Union for a long time, and even today, phages are 
used in Georgia to treat some infections [65]. Various 
studies have been conducted on the use of phages in ani-
mal models to evaluate the safety and efficacy of phages 
to counteract both major Gram-positive and Gram-neg-
ative clinical pathogens. Among these, P. aeruginosa was 
particularly important due to its high antibiotic resist-
ance, high mortality, and high production of extensive 
biofilms in nosocomial infections. Jeon et  al. evaluated 
two novel bacteriophages BФ-R656 and BФ-R1836 in the 
survival of acute pneumonia mouse models infected with 
extensively drug-resistant (XDR) P. aeruginosa in vitro, in 
silico, and in  vivo. Both phages exhibited potent inhibi-
tory activity and lysed XDR P. aeruginosa strains isolated 
from pneumonia patients. Furthermore, researchers 
developed two models of in  vivo infection. The results 
demonstrated that BФ-R656 and BФ-R1836 eliminated 
XDR P. aeruginosa strains in Galleria mellonella lar-
vae and acute pneumonia mice models. These phages 
were able to remove the host XDR P. aeruginosa biofilms 
extensively. So, it was suggested that these phages could 
be used as a biocontrol agent not only to inhibit biofilm 
formation on medical devices and hospital environments 
but also to eliminate biofilm-associated infections in the 
body [65].
In another study, the phage PELP20 was evaluated to 
counter chronic lung infections with P. aeruginosa in 
a mice model. The results of this study confirmed that 
the phage had antimicrobial activity on P. aeruginosa, 
and the 3-log phage reduced the biofilm. This indicates 
that phage PELP20 can kill the biofilm-related bacteria 
present in the lungs of CF patients [62]. Besides, phage 
ФPan70, a temperate phage, was used to control MDR P. 
aeruginosa infection in planktonic, biofilm, and mouse 
burn models. The significant results showed that the 
phage affected both planktonic and biofilm cells and sig-
nificantly reduced the bacterial population. Interestingly, 
the phage resulted in the survival of the burned mice 
from 80 to 100%. Of note, the reason for the difference 
in the effect of phage on different isolates was that the 
phages were strain-specific, and due to the differences in 
the amount of exopolysaccharide, the effect of phage was 
different on a variety of biofilms. The researchers specu-
lated that phages could inhibit the spread of bacteria into 
the bloodstream, and the phages inoculated in the site of 
infection would confine the high concentration of bac-
teria and enhance the immune response and cutaneous 
mastocytosis [66].
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Alemayehu et  al. tested the effects of two bacterio-
phages (ФMR299-2 and ФNH-4) to counteract P. aer-
uginosa biofilm in murine lungs; they demonstrated 
that these two phages killed all clinical isolates (mucoid 
and non-mucoid isolates). The phage cocktail was effec-
tive in killing mucoid and non-mucoid strains growing 
in the cystic fibrosis bronchial epithelial CFBE41o-cell 
line. Also, the phage cocktail showed a lethal effect on 
P. aeruginosa in murine lungs, and this bacterium was 
effectively cleared from the lungs after six hours. They 
explained that the phages had to penetrate the biofilm 
exopolysaccharide to be effective; this required a longer 
time (22 to 24 h) for the phage to be exposed to the bio-
film and clear P. aeruginosa from infected rat lungs. Also, 
it has been suggested that the use of diverse phages usu-
ally results in the occupation of different bacterial recep-
tors; thus, it requires independent mutations to generate 
phage resistance. As a result, using different phages in 
one combination can control the bacterial population if 
there is no resistance [67]. In 2018, the effect of the cock-
tail containing six different phages (PYO2, DEV, E215, 
E217, PAK_P1, and PAK_P4) on the reduction of P. aer-
uginosa biofilm formed in acute respiratory infection 
model in mice and bacteremia in wax moth (Galleria mel-
lonella) larvae was studied. The results showed that these 
phages alone could lyse P. aeruginosa in both planktonic 
and biofilm forms. The phage cocktail was also found to 
be effective on MDR and mucoid phenotype of P. aerugi-
nosa isolates. This cocktail was superior to the individual 
phages in destroying biofilms, and it decreased treatment 
time in mice. Researchers noted that the phage cocktail 
reduced different degrees of biofilms; it was able to enter 
the biofilm, destroy its biomass, and reach the bacteria 
embedded inside [68]. Another study was performed to 
evaluate the effect of bacteriophages on MDR P. aerugi-
nosa biofilm in a mouse wound model. The results exhib-
ited that the phage cocktail had an inhibitory effect on 
the biofilm created in mouse wounds, and the count of 
bacteria was decreased after treatment [69].
Overall, bacteriophages alone and in combination 
together effectively control XDR and MDR P. aeruginosa 
infections in planktonic and biofilms forms in the ani-
mal models. Therefore, human infections that are asso-
ciated with the P. aeruginosa biofilm, particularly XDR 
and MDR infections, such as lung and wound infections, 
are associated with therapeutic problems, and they can 
be the potential future targets of phage therapy. As the 
results of the in  vitro studies show, the use of bacterio-
phage cocktails in animal models have shown better per-
formance, so it is recommended that it be used more in 
future studies. Table  2 summarizes some of the studies 
that used bacteriophages to destroy biofilms of the most 
important bacterial pathogens. Infection caused by the 
biofilm of these bacteria, along with the P. aeruginosa 
biofilm, is one of the most important causes of chronic 
and MDR infections.
Use of combination therapy of antibiotics 
and bacteriophages to inhibit P. aeruginosa biofilm
Applying a combination of different substances with anti-
biotics to increase their effectiveness on MDR bacteria 
has received much attention [88]. Furthermore, combi-
nation therapy can also be useful in destroying biofilms 
[89, 90]. Therefore, using various compounds, which are 
capable of destroying the EPS and increasing the permea-
bility of the biofilm, can boost the antibiotic function, and 
previous studies have reported that bacteriophages can 
also enhance antibiotic performance on biofilms. Tamta 
and his colleagues reported that the use of bacterio-
phages and antibiotics helped inhibit MDR P. aeruginosa 
biofilm in a patient with diabetes mellitus type 2 who was 
also diagnosed with relapsing right knee periprosthetic 
joint infection and chronic osteomyelitis. In this patient, 
bacteriophage was administered locally during surgery, 
and a bacteriophage solution was applied every 8  h for 
five days. The results of isothermal microcalorimetry 
showed that bacteriophages can help destroy biofilm, 
and pretreatment of P. aeruginosa biofilm with phages, 
eight hours before colistin exposure, demonstrated the 
most substantial reduction of biofilm biomass. In this 
presented case, the combined use of phage, surgery, and 
conventional antibiotics eradicated the infection, and no 
phage side effects were observed. However, surgery and 
antibiotic treatment alone was not sufficient and led to 
numerous therapeutic failures [91].
In another study, a combination of bacteriophage vB_
PaM_EPA1 and antibiotics that were selected based on 
their mechanism of action was used to destroy the biofilm 
of P. aeruginosa [92]. Using bacteriophages and antibiot-
ics alone showed a modest effect on biofilm destruction, 
but a profound improvement in the killing was observed 
when applied simultaneously or sequentially. Notably, 
increasing the concentration of antibiotics when used in 
combination with bacteriophages did not have a more 
significant inhibitory effect on the biofilm. This can be 
related to phage replication inhibition phenomena that 
protein and DNA synthesis inhibition antibiotics, which 
results in the suppression of bacteriophages [92–94]. Fur-
thermore, the highest inhibitory effect on biofilm was 
observed when antibiotics were added sequentially after 
phage treatment. So, combined treatments with sequen-
tial application of phage and antibiotics (Fig.  1) have a 
better killing effect than the concurrent application. No 
depolymerase was detected in the bacteriophages used 
in this study. Therefore, it seems that vB_PaM_EPA1 
reaches the bottom layers of the biofilm through the 
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Table 2 Some studies using phage therapy to inhibit the biofilm of the most important bacterial pathogens
Biofilm forming
bacteria
Bacterial Properties Phage Outcome References
Acinetobacter baumannii XDR A. baumannii Phage AB1801 This phage inhibited biofilm forma-
tion and reduced preformed bio-
films in a dose-dependent manner
[70]
MDR A. baumannii Phage lysin PlyF307 Treatment with PlyF307 was able 
to significantly reduce planktonic 
and biofilm of A. baumannii, both 
in vitro and in vivo
[71]
A. baumannii strain AIIMS 7 Lytic bacteriophageAB7-IBB1 The phage affected A. bauman-
nii biofilm formation on an abiotic 
(polystyrene) and biotic (human 
embryonic kidney 293 cell line) 
surface
[72]
Clinical isolate of A. baumannii strain 
AIIMS 7
Phage AB7-IBB2 The phage could inhibit A. bauman-
nii biofilm formation and disrupt 
preformed biofilm as well
[73]
Klebsiella pneumoniae P DR K. pneumonia UA168 The phage KP168 After 48 h of co-cultivation of this 
phage and the host bacteria at each 
MOI, the inhibition rates of bio-
film were similar, with an average of 
about 45%
[74]
MDR K. pneumonia Depolymerase Encoded by
Bacteriophage SH-KP152226
This enzyme showed specific enzy-
matic activities in the depolymeriza-
tion of the K. pneumoniae capsule 
and was able to significantly 
inhibit biofilm formation and/or 
degrade formed biofilms
[75]
An environmental isolate of K. pneu-
moniae ShA2 strain
TSK1 bacteriophage Post-treatment with TSK1 against 
different age K. pneumoniae biofilms 
reduced 85–100% biofilm biomass. 
Pre-treatment of TSK1 bacte-
riophage against the biofilm of K. 
pneumoniae reduced > 99% biomass 
in the initial 24 h of incubation
[76]
MDR K. pneumoniae KP/01 Bacteriophage ZCKP1 This phage reduced bacterial counts 
and biofilm biomass (> 50%) when 
applied at a high multiplicity of 
infection (50 PFU/CFU)
[77]
A clinical strain of K. pneumoniae Bacteriophage Z Phage Z reduced biofilm biomass 
twofold and threefold after 24 and 
48 h, respectively
[78]
Staphylococcus aureus MRSA UPMK_1 and UPMK_2 phages Both bacteriophages were able to 
destroy biofilms using their lytic 
enzymes
[79]
MRSA and MSSA Bacteriophage CSA13 This bacteriophage removed over 
78% and 93% of MSSA and MRSA 
biofilms in an experimental setting, 
respectively
[80]
MRSA ATCC 43,300 Bacteriophage Sb-1 This phage showed a synergistic 
effect with antibiotics on eradicat-
ing MRSA biofilm, direct killing 
activity on ≈ 5 × 105 CFU/mL 
persisters cells, and degraded MRSA 
polysaccharide matrix
[81]
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biofilm void spaces [95], thereby replicates in the deeper-
layer of biofilm, interrupt the structure of the biofilm 
and enhance the performance of the antibiotics [92]. 
In another study, phage PEV20 and ciprofloxacin were 
used to inhibit the biofilm of P. aeruginosa isolated from 
wound and cystic fibrosis patients. The results showed 
that combined antibiotic phage treatment enhanced 
biofilm eradication compared with single ciprofloxacin 
treatment. This phenomenon can be as a result of the low 
penetration of this antibiotic into the biofilm and bacteria 
on the inner layers of biofilm, which show high antibiotic 
resistance due to low metabolic activity. However, when 
bacteriophages reduce the integrity of the extracellular 
matrix, the bacteria in the inner layers of the biofilm are 
exposed to food and oxygen and become metabolically 
active; and this can lead to induction of antimicrobial 
effects of ciprofloxacin and phage [96, 97]. On the other 
hand, some planktonic bacterial cells were highly suscep-
tible to PEV20. However, after biofilm formation, phage 
treatment alone was ineffective, and this may indicate 
that phage monotherapy may lead to resistance to bacte-
riophages and result in a subsequent increase in bacterial 
and biofilm density over time; therefore, using cocktails 
of phages may be helpful in this regard [61]. It should be 
noted that using a combination of bacteriophages and 
tobramycin had no change in the inhibitory effect on the 
bacterial biofilm compared with using tobramycin alone; 
this may indicate the high penetration of fluoroquinolo-
nes into P. aeruginosa biofilm [97].
In a similar study, a combination of bacteriophages 
((ATCC 12,175-B1 (Pa1), ATCC 14,203-B1 (Pa2), and 
ATCC 14,205-B1 (Pa11)) and ciprofloxacin was used to 
destroy the biofilm of different P. aeruginosa isolates. The 
results showed that bacteriophages had a better inhibi-
tory effect on biofilm than antibiotics, and when used in 
combination, they performed better than applying antibi-
otics alone. Using phages before antibiotics have the best 
inhibitory effect on the biofilm because it seems that, in 
the large bacterial population, phages can increase to a 
greater extent than the condition of adding phages after 
antibiotic therapy. Therefore, it seems that the phage 
application should precede antibiotic treatment. Of note, 
it is reported that bacteriophages perform better when 
used in the early stages of biofilm formation, and the 
large colonies seem to provide spatial refuges that protect 
the bacterial host from phage infection, which reduces 
the effect of phage therapy for the treatment of mature 
biofilms [98]. Chaudhry et al. reported that the combined 
MDR, Multi-drug resistant; PDR, Pan-drug resistant; MRSA, Methicillin-resistant S. aureus; MSSA, Methicillin-susceptible S. aureus; VRE, Vancomycin-resistant 




Bacterial Properties Phage Outcome References
Escherichia coli E. coli MG1655 and MDR UPEC strain 
390G7
Bacteriophage vB_EcoP-EG1 vB_EcoP-EG1eliminated biofilm of 
these bacteria. The median biofilm 
biomass reduction was about 60% 
and 50% for E. coli MG1655 and for 
clinical isolate 390G7 after 24 h, 
respectively
[82]
E. coli TG1 T3 bacteriophage T3 at lower bacteriophage titers 
 (103 PFU/ml) inhibited the produc-
tion of biofilm
[83]
E. coli 30 vB_EcoM-UFV017 (EcoM017) This phage reduced the bacterial 
growth and the quantity of bio-
film formed by E. coli in 90.0% and 
87.5%, respectively
[84]
Enterococcus faecalis E. faecalis clinical strains vB_EfaH_EF1TV This phage infected E. faecalis and 
degraded biofilm formed by this 
bacterium
[85]
VRE E. faecalis Vancomycin-phage EFLK1 This phage, in combination with 
vancomycin, was synergistically 
effective against VRE planktonic 
and biofilm cultures
[86]
E. faecalis and Enterococcus clinical 
isolates
vB_EfaS-Zip and vB_EfaP-Max The cocktail of these phages reduced 
2 and 1 log CFU/mL E. faecalis load 
in biofilms formed in the wound 
after 3 and 6 h of treatment, respec-
tively, and significantly reduced 
cell concentration in dual-species 
biofilm
[87]
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use of bacteriophages and antibiotics that are commonly 
used to treat pseudomonas infection leads to pharmaco-
dynamics synergy and could be useful in destroying the 
P. aeruginosa PA14 biofilm [93]. Antibiotics had only a 
limited effect on the biofilm when used alone. Still, the 
combination of bacteriophage plus ciprofloxacin and 
Fig. 1 Anti-biofilm mechanisms of bacteriophages. a Bacteriophages inhibit biofilm formation by inhibiting quorum sensing and reducing cellular 
communication. b Combined treatments with sequential application of phage and antibiotics have a killing efficacy on P. aeruginosa biofilm. c 
Combined use of bacteriophages with molecules with anti-biofilm properties can help biofilm destruction. d Bacteriophages can penetrate the 
inner layers of the biofilm through the biofilm void spaces without destroying the external matrix and replicate in the deeper-layer of biofilm
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ceftazidime reduced bacterial density below that of the 
best single antibiotic treatment. On the other hand, the 
combination of bacteriophages with gentamicin and 
colistin did not improve the inhibitory effect of antibi-
otics on biofilms. It should be noted that to simulate the 
condition of the patient’s body and its impact on treat-
ment, the P. aeruginosa PA14 was added to the conflu-
ent monolayers of human nasopharyngeal cells, and 
biofilms were formed. All five antibiotics alone inhibited 
the growth of bacteria on these cells, and simultaneous 
treatment with the phage and tobramycin significantly 
increased the efficacy of antibiotics in killing the bacte-
ria. Noteworthy, the results of this study, like previous 
studies, showed that when bacteriophages were admin-
istrated before antibiotics for treating biofilm infections, 
they could have a better effect than simultaneous admin-
istration [93, 99, 100].
Finally, Coulter et  al. used a combination of bacte-
riophage PB-1 and tobramycin to inhibit P. aeruginosa 
PAO1 biofilm. The outcomes of this study showed that 
combination therapy was not more helpful than the 
administration of antibiotics alone, and this may be due 
to the EPS activity that blocks the ability of the phage to 
access their specific receptors. However, the combined 
use of PB-1 and tobramycin resulted in a 60% and 99% 
decrease in tobramycin and phage resistant cell, respec-
tively, compared to the use of tobramycin or phage alone. 
Thus, combined tobramycin-bacteriophage can sig-
nificantly reduce the emergence of antibiotic and phage 
resistant cells; however, the reduction in biomass was 
dependent on the phage-host system [101]. Therefore, 
the results of different studies show that the combined 
use of P. aeruginosa specific bacteriophages and effec-
tive antibiotics on this bacterium can improve antibi-
otic efficacy and reduce antibiotic-resistant bacteria in P. 
aeruginosa biofilm. Although most studies have focused 
on pure bacterial cultures, the presence of polymicro-
bial biofilm infections, such as wound infection, is very 
problematic because these biofilms usually have higher 
antibiotic resistance than monoculture infections [60, 
101, 102]. In this regard, the combined use of bacterio-
phage and antibiotics in future studies for the inhibition 
of mixed cultures should be considered further.
Other combination therapies to increase 
the efficacy of phage therapy on P. aeruginosa 
biofilms
In addition to the combined use of antibiotics and phages, 
recent studies have used other methods to increase the 
efficacy of bacteriophages on P. aeruginosa biofilms. For 
example, James and his colleagues engineered an inject-
able hydrogel capable of encapsulating P. aeruginosa 
(PsAer-9) bacteriophage to treat bone infections caused 
by this bacterium. Bacteriophages (ΦPaer4, ΦPaer14, 
ΦPaer22, ΦW2005A) retained their antimicrobial ability 
after being encapsulated in a hydrogel, and the hydrogel 
formula controlled the rate of release. Bacteriophage-
encapsulating hydrogels effectively lyse P. aeruginosa in 
both planktonic and biofilm phenotypes, in vitro, without 
affecting the metabolic activity of human mesenchymal 
stromal cells. Furthermore, hydrogels containing a com-
bination of P. aeruginosa bacteriophage significantly (4.7 
fold) reduced bacteria counts in the murine radius seg-
mental bone defect in comparison to bacteriophage-free 
hydrogels, and immune responses to bacteriophages were 
not observed. This indicates the low toxicity effect of this 
compound on eukaryotic cells. Notably, in this study, the 
inhibitory role of bacteriophage-encapsulating hydrogels 
as prophylaxis for inhibiting the formation of P. aerugi-
nosa biofilm in bone was demonstrated. In future studies, 
the role of this hydrogel in controlling established infec-
tions should be considered [103]. Another study reported 
that the combination uses of vB_PaeP_PAO1-D bacterio-
phages and chestnut honey could be effective in inhibit-
ing P. aeruginosa PAO1 biofilm and can be a promising 
alternative for topical treatment of wound infection. The 
results showed that honey and bacteriophages, syner-
gically, increase the antimicrobial effect of each other 
because they can destroy biofilms using different mecha-
nisms. In this regard, phages infect and destroy bacteria 
through host-receptor recognition. On the other hand, 
honey, as another antimicrobial agent, induce destruction 
in bacteria by other distinct mechanisms such as oxida-
tive stress, osmotic pressure, acidity, hydrogen peroxi-
dase release, and presence of methylglyoxal (MGO). So, 
honey seems to increase the binding of bacteriophages to 
their specific receptors by destroying the EPS of the bio-
film, and the topical use of phage-honey formulation can 
be useful for the treatment of chronic wounds since bac-
teriophages destroy MDR bacteria and honey accelerates 
the wound healing process [104].
Interestingly, in another study, the combination of bac-
teriophage and chlorine disinfectants was used to destroy 
the biofilm of P. aeruginosa. Chlorine compounds are 
one of the most commonly used disinfectants in hospi-
tals, and their combination with bacteriophage was more 
efficient in reducing P. aeruginosa biofilm formation. 
There were significant differences between combination 
treatments and single treatment. Chlorination treat-
ments were not capable of destroying the pre-existing 
P. aeruginosa biofilms because the EPS produced in the 
biofilm prevents the penetration of chlorine into the bio-
film. Nevertheless, in combination with bacteriophages, 
their efficacy increased and eventually led to cell mem-
brane disruption and cell lysis. Therefore, the combined 
use of bacteriophage and chlorine disinfectants enhances 
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biofilm cell lysis and destruction of P. aeruginosa bio-
film, which can be used as a promising method for the 
destruction of bacterial biofilm [105]. Phage, belong-
ing to the Podoviridae family, inspired gold nanoparti-
cles (AuNPs) were another compound reported to have 
the capability to destroy the P. aeruginosa MTCC 728 
biofilm. In this study, phage lysate was used to synthe-
size nanoparticles, and it exhibited higher antimicrobial 
activity against P. aeruginosa compared to bacterial cell-
mediated AuNPs. Furthermore, phage inspired AuNPs 
inhibited the bacterial biofilm formation on the glass 
surface. AuNPs can inhibit bacterial biofilm due to their 
toxic effects on bacterial cells, and bacteriophages can 
help them perform their inhibitory function on the bio-
film at a lower concentration. Thus, it is reported that 
phage inspired AuNPs synthesis may serve as potential 
therapeutic agents against the biofilm-forming human 
bacterial pathogens [106].
In another study, QQ lactonase (SsoPox-W2631) 
were used to destroy the biofilm of clinical isolates and 
P. aeruginosa and increase the effectiveness of bacterio-
phages and antibiotics on them. The results showed that 
SsoPox-W263 reduces pyocyanin, protease, and elastase 
production in antibiotic and bacteriophage-resistant 
P. aeruginosa strains. Furthermore, this enzyme can 
destroy more than 70% of the biofilms formed in this 
bacterium and increase the effectiveness of bacterio-
phages and antibiotics on P. aeruginosa biofilms [107]. 
Finally, another study reported that xylitol could also 
enhance bacteriophage function for the destruction of 
stable mixed-species biofilm of K. pneumonia and P. aer-
uginosa. Using non-depolymerase producing phage Pa29 
was not capable of destroying P. aeruginosa biofilm due 
to limited penetration in the deeper layer. Nonetheless, 
when Pa29 was used with K. pneumonia specific depoly-
merase producing phage KPO1K2, an enhanced effect 
was observed on the destruction of the mixed-species 
biofilm. Therefore, it was suggested that the capsular 
depolymerase present in Klebsiella-specific bacterio-
phage could increase the permeability of Pa29 due to the 
destruction of the top layer of the biofilm. Furthermore, 
xylitol helped Pa29 to destroy the biofilm of P. aerugi-
nosa. Still, they were ineffective in mixed-species biofilm 
destruction because of the distinct spatial distribution 
pattern adopted by the two organisms in mixed-species 
biofilm. Hence, the combined use of bacteriophages and 
xylitol can effectively inhibit P. aeruginosa biofilm, and 
they can be used as one of the therapeutic strategies 
for tackling chronic infections caused by mixed-species 
bacterial biofilms [108]. Therefore, in addition to the 
combined treatment of bacteriophages and antibiotics, 
which are effective in destroying the P. aeruginosa bio-
film, the simultaneous use of bacteriophages with natural 
substances, nanoparticles, and disinfectants can also 
increase the chances of biofilm destruction of the bac-
terium (Fig.  1); however, further studies are needed to 
confirm this finding. Besides, a combination of various 
natural substances, nanoparticles, and other chemicals, 
which have been reported in recent studies, may have 
anti-biofilm properties along with bacteriophages can be 
used in future studies to destroy the biofilm of MDR P. 
aeruginosa.
Phage therapy limitation for inhibition of bacterial 
biofilm
As mentioned in the previous sections, phages are con-
sidered as a potential agent for prevention and control-
ling the biofilm. Still, there are some obstacles in the 
application of phages for biofilm control.
Biofilm extracellular matrix limit the diffusion
The extracellular polymeric substance known as EPS 
consists of 90 percent of the biofilm mass and creates a 
three-dimension shape of biofilm. EPS prevents the diffu-
sion of the antimicrobial agents through bacteria by cov-
ering bacteria cells [109–111]. Furthermore, phages may 
have initial reversible interaction with some components 
like capsule polysaccharide, teichoic acids, and lipopoly-
saccharides, but cell wall components are necessary for 
irreversible attachment. The existence of the mentioned 
components in the matrix can limit the phage entrance 
into biofilm cells [109, 112]. Hu et al., in a study on dif-
fused properties of phages, reported that similar to the 
antibiotics, slow penetration through biofilm could be 
a problem for phages. Also, they suggested that phage 
penetration is dependent on both phage morphology 
and biofilm density; as the density increase, the diffusion 
becomes more difficult [113].
Narrow host range
The molecules on the surface of bacteria, such as 
lipopolysaccharide and peptidoglycan components, 
outer membrane proteins, and teichoic acids, could be 
the attachment sites for the phage tail [114, 115]. Also, 
the host range is determined by the specificity of phage 
receptors. Furthermore, some phages have a broad spec-
trum, while some other phages have a narrow spectrum 
of host range. Narrow host range could be problematic, 
especially in polymicrobial biofilms, which are formed on 
medical devices [115, 116]. Besides, in most of the infec-
tious biofilms, there are two or multiple bacterial species 
that make the clearance with the phage therapy challeng-
ing [117]. Choosing one single phage, which can destroy 
various extracellular polymers and using it in phage cock-
tails, can be the right solution against polymicrobial bio-
films [115, 118].
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Sub‑populate phage resistance in biofilm
Becoming resistant to phages is necessary for the sur-
vival of bacteria, and this happens by four different 
mechanisms. These mechanisms give bacteria adoption 
to phages and create a phage resistance mutant [109, 
119]. There are reports about the rapid growth of phage 
resistance sub-populate after the primary reduction of 
biofilm cells that were treated with phages [58, 61, 115, 
120]. As Fu et  al. studied the formation of biofilm on 
the hydrogel-coated catheter, they observed that after 
24  h in the phage treated group, viable biofilm counts 
were decreased compared to the untreated group. On 
the other hand, phage resistant isolates were recovered 
from the biofilm. Also, when they used a cocktail con-
sisting of five different phages, biofilm cell density was 
reduced by 99.9%, but they found few isolates resistance 
to these phages [61]. In another study in two isolates of 
phage resistant P. aeruginosa, genetic analyzes revealed 
that mutations in pilT and galU genes are associated 
with resistance. Furthermore, these genes are associ-
ated with pilus motility and LPS formation, respec-
tively. Also, they can act as phage receptors [121].
Additionally, Lacqua et  al. found a subpopulation of 
E. coli strain that is resistant to lysis of two phages, and 
it seems that the biofilm formed by fimbria could be 
a potential strategy for bacteria to escape phage ther-
apy. They suggested that biofilm formation could be a 
mechanism for phage resistance alongside with specific 
mechanisms like changing the receptor or production 
of DNA restriction enzymes [120]. It seems that the 
application of phage cocktails could be an excellent 
solution for preventing this problem [109, 122].
Reduction in metabolic activity of biofilm bacteria 
cell
Since phage infection strictly depends on the growth 
condition of its host, one of the obstacles in the suc-
cessful use of phage therapy against bacterial biofilm is 
the reduction of metabolism. Bacteria that are present 
in biofilms are under nutrient-limited conditions, and 
they grow slowly [89, 117, 123, 124]. On the other hand, 
phage infection is dependent on the resources of bacte-
ria, which is directly related to the physiological state, 
and it is expected that phage infection in planktonic 
bacteria is more efficient than biofilm bacteria [125]. 
The result of one study showed that phage infection of 
Pseudomonas fluorescens in planktonic mode increased 
cell lysis; meanwhile, in biofilm cell lysis, it was nota-
bly lower [125]. Also, phage release after the bacterial 
infection was much higher in the exponential phase 
rather than in the stationary phase and decline phase 
[125]. In another study by los et al., it was revealed that 
starvation of phage could cause severe inhibition of 
phage lytic development [123].
Furthermore, Cerca et  al. studied Staphylococcus epi-
dermidis, and they suggested that lysis of bacteria in 
biofilm is slower than planktonic culture, and it is prob-
ably due to low metabolism in biofilm cells. Neverthe-
less, cells are more sensitive in the exponential growth 
phase rather than the stationary growth phase in plank-
tonic mode [118]. In both Sillankorva et  al. and Cerca 
et al. studies, biomass reduction, was equal in biofilm and 
planktonic mode, and it seemed that biomass reduction 
was dependent on cells’ physiological state rather than 
biofilm phenotype [117, 118, 125].
Inhibition of phage infection via Quorum sensing 
(QS) in biofilm
Many bacteria use QS as a communication system 
between cells with extracellular chemical molecules 
called auto-inducers. QS allows bacteria to coordinate 
gene expression and density of cells population [126, 
127]. Furthermore, it is well known that QS controls 
biofilm formation, growth, and dispersion, and there 
are suggestions for inhibiting biofilm formation by disa-
bling QS [128]. In a study on the QS effect on bacteria’s 
antiphage mechanism, the results demonstrated that in 
response to N-acyl-L-homoserine lactone (AHL), which 
is the QS signal, reduction of λ phage receptor happened 
in E. coli. This led to an increase of uninfected bacteria 
after the phage challenge, and AHL could reduce the 
chance of infection in a broader range of phages [129]. 
Notably, the QS effect against phages needs more investi-
gations and descriptions for other bacteria species [109]. 
Overall, QS could create biofilm and use two different 
methods for inhibiting the phage effect on biofilm. First, 
it can reduce metabolic activity and recourse optimiza-
tion in the biofilm that leads to decreased phage infection 
efficiency; second, it can regulate antiphage mechanisms 
[109].
Conclusion and perspective
Biofilm is one of the leading causes of antibiotic resist-
ance and chronic infections. Because of the inefficacy of 
antibiotics to inhibit bacterial biofilm, new strategies are 
needed to combat it. Recent studies have identified phage 
therapy as one of the effective methods for the destruc-
tion of P. aeruginosa biofilm. As noted above, there are 
still limitations to the widespread use of phage therapy, 
and a focus is needed to address these issues in future 
studies. The use of new strategies to enhance the efficacy 
of bacteriophages on the biofilm of P. aeruginosa is help-
ful. Furthermore, it is recommended that future studies 
use phage therapy to prevent chronic infections caused 
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by P. aeruginosa biofilm so that hopefully it paves the way 
for more using this therapeutic approach.
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